{"id":"NCT02971683","sponsor":"Bristol-Myers Squibb","briefTitle":"Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy","officialTitle":"A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-04","primaryCompletion":"2020-07-27","completion":"2022-08-02","firstPosted":"2016-11-23","resultsPosted":"2021-09-17","lastUpdate":"2023-10-30"},"enrollment":149,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Polymyositis","Dermatomyositis","Autoimmune Necrotizing Myopathy","Overlap Myositis","Juvenile Myositis Above the Age of 18"],"interventions":[{"type":"DRUG","name":"Abatacept subcutaneous","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Abatacept subcutaneous + Standard Treatment","type":"ACTIVE_COMPARATOR"},{"label":"Placebo of Abatacept subcutaneous + Standard Treatment","type":"PLACEBO_COMPARATOR"}],"summary":"Trial to Evaluate the Efficacy and Safety of Abatacept subcutaneous (SC) in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy","primaryOutcome":{"measure":"Number of Participants Achieving International Myositis Assessment and Clinical Studies Definition of Improvement (IMACS DOI) at Week 24 Without Rescue","timeFrame":"From first dose to 24 weeks after first dose. (Approximately 169 days)","effectByArm":[{"arm":"Abatacept + Standard Treatment","deltaMin":42,"sd":null},{"arm":"Placebo + Standard Treatment","deltaMin":31,"sd":null}],"pValues":[{"comp":"OG000","p":"0.083"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":79,"countries":["United States","Australia","Brazil","Czechia","France","Germany","Italy","Japan","Mexico","South Korea","Sweden"]},"refs":{"pmids":[],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":138},"commonTop":["Nasopharyngitis","Headache","Influenza","Back pain","Fall"]}}